Drug Profile
Research programme: GABA A alpha-5 modulators - AgeneBio
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer AgeneBio
- Class Antidementias; Antipsychotics; Behavioural disorder therapies; Small molecules
- Mechanism of Action GABA A alpha 5 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Autistic disorder; Mild cognitive impairment; Schizophrenia
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Sep 2021 No recent reports of development identified for preclinical development in Autistic-disorder in USA
- 28 Sep 2021 No recent reports of development identified for preclinical development in Mild-cognitive-impairment in USA